Kenvue Inc. is a consumer health company globally.
| Revenue (TTM) | $15.41B |
| Gross Profit (TTM) | $9.00B |
| EBITDA | $3.48B |
| Operating Margin | 19.40% |
| Return on Equity | 15.60% |
| Return on Assets | 6.99% |
| Revenue/Share (TTM) | $8.04 |
| Book Value | $5.50 |
| Price-to-Book | 3.22 |
| Price-to-Sales (TTM) | 2.22 |
| EV/Revenue | 2.69 |
| EV/EBITDA | 12.89 |
| Quarterly Earnings Growth (YoY) | 8.50% |
| Quarterly Revenue Growth (YoY) | 3.00% |
| Shares Outstanding | $1.92B |
| Float | $1.92B |
| % Insiders | 0.07% |
| % Institutions | 95.92% |
Volatility is currently contracting
Kimberly-Clark has offered concessions to address EU antitrust concerns about its $40 billion bid for Tylenol maker Kenvue , a filing on the European Commission website showed on Wednesday.
While investors pile into pricey AI darlings, a handful of battle-tested Dividend Kings have quietly slipped to levels that scream value, and Wall Street analysts see serious upside ahead for 2027.
Johnson & Johnson has raised its dividend for 64 straight years, but faces billions in talc-related litigation liabilities. Kenvue offers a higher yield of 4.71%, but its pending acquisition by Kimberly-Clark creates uncertainty about its dividend outlook.
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock. The quarterly dividend is payable on October 2, 2026, to shareholders of record as of the close of business on September 21, 2026. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson.
KVUE's trusted brands, innovation and productivity initiatives support growth as it strengthens its consumer health portfolio and global reach.
U.S. equities posted double-digit quarterly gains despite volatility stemming from the Iran conflict. Key contributors include Infineon Technologies, Teradyne and Walmart. Key detractors include Micron Technology, Intel and Sandisk.
Kenvue's profit margins and cash flow improved in the first half, but modest sales growth, debt and uneven segment trends keep the risk-reward balanced.
KVUE nears its planned combination after shareholder and U.S. antitrust clearances, while margin, debt and legal risks temper the Q4 2026 outlook.
Australia's competition regulator on Wednesday approved Kimberly-Clark's proposed $40 billion takeover of Kenvue , on condition the company divests Kenvue's Carefree and Stayfree period care brands in the country to address competition concerns.
Kimberly-Clark has asked EU regulators permission for its proposed $40 billion takeover of Tylenol maker Kenvue, documents on the EU Commission's website showed.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KVUE and any ticker you trade — then tracks every position and per-strategy win rate.
